All Resources
Access a curated library of reports, policy submissions, data insights, and other materials informing Canada’s life sciences ecosystem.
IMC Response to PMPRB Interim Approach Consultation
IMC’s members continue to have significant concerns regarding changes to the PMPRB and future Guidelines that will implement the revised schedule of international reference countries.
Optimizing Patient Access to Precision Therapies: Preparing for the Emerging Era of Advanced Testing
This policy note characterizes Canada’s current testing infrastructure and its limitations, which include that it hinders current and future patient access to the best available treatments.
PMPRB Guidelines Notice and Comment
IMC opposes a January 15, 2021 proposal to redefine ‘gap’ medicines and change the timeline for compliance – which halves the transition period to six months.
IMC Response to PMPRB 2020 Draft Guidelines
IMC critiques the June 2020 Federal Court decision that confidential third-party payments are ultra vires the Patent Act.
